GlassScriptPhysician profile
Erin M Cannington
NPI 1629165675
$13,026.69
in general payments reported to CMS, 2019-2025
38 companies · $2,726 in 2025
The $2,726 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $1,302 · 2021: $1,429 · 2022: $1,695 · 2023: $2,439 · 2024: $2,626 · 2025: $2,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,437 · Honoraria: $175 · Consulting Fee: $100 · Education: $78.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,437.23 |
| Honoraria | $175.00 |
| Consulting Fee | $100.44 |
| Education | $78.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,423.62 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,388.13 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $1,288.70 | 2019-2025 | Dupixent |
| Octapharma USA, INC. | $1,229.47 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $983.42 | 2020-2025 | Cuvitru, Glassia, Takhzyro |
| Pfizer INC. | $744.30 | 2019-2025 | |
| Grifols USA, LLC | $712.93 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Abbvie INC. | $609.36 | 2021-2025 | Rinvoq |
| Csl Behring | $578.37 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Biocryst US Sales Co., LLC | $542.33 | 2022-2025 | Orladeyo |
| Genzyme Corporation | $538.20 | 2020-2025 | |
| Amgen INC. | $461.00 | 2022-2025 | Tezspire |
| Leo Pharma INC. | $293.04 | 2022-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $263.39 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $210.80 | 2022-2024 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Cannington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.